Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent

Expert Review of Clinical Pharmacology

Volumn 1, Issue 4, 2008, Pages 479-489

  Tan, Tina Q ^a   Yogev, Ram ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Enterococcus; Gram positive bacteria; Linezolid; Oxazolidinone; Staphydococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CORTICOSTEROID; EPEREZOLID; GLYCOPEPTIDE; LINEZOLID; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FUNCTION TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; PANCREATITIS; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PROTEIN SYNTHESIS INHIBITION; RIBOSOME SUBUNIT; SEROTONIN SYNDROME; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; TASTE DISORDER; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 49449092607     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.4.479     Document Type: Article

References (110)

1. Jacobs MR, Good CE, Beall B et al. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. Clin. Microbiol. 46, 982-990 (2008).
2. Graham PL, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann. Intern. Med. 144, 318-325 (2006).
3. Sievert DM, Rudrik JT, Patel JB et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46, 668-674 (2008).
4. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with redued vancomycin susceptibility. J. Antimicrob. Chemother. 40, 135-146 (1997).
5. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin. Infect. Dis. 39, 539-545 (2004).
6. Mutnick AH, Biedenbach DJ, Turnidge JD et al. Spectrum and potency evaluation of a new oxazolidinone, linezolid; report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microb. Infect. Dis. 43, 65-73 (2002).
7. Arbeit RD, Maki, D, Tally MD et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38, 1673-1681 (2004).
8. Delgado G Jr, Neuhauser MM, Bearden DT et al. Quinupristin-dalfopristin: an overview. Pharmacotherapy 20, 1469-1485 (2000).
9. Allington DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin. Therapeutics 23, 24-44 (2001).
10. Thien-Ly D, Fung HB, Mehta D et al. Tigecycline: a glycylcycline antimicrobial agent. Clin. Therapeutics 28, 1079-1106 (2006).
11. Zhanel GG, Karlowsky, Rubinstein E et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev. Anti Infect. Ther. 4, 9-25 (2006).
12. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64, 63-88 (2004).
13. Bogdanovich T, Ednie LM, Shapiro S et al. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49, 4210-4219 (2005).
14. Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46, 647-655 (2008).
15. Chambers HF. Ceftobiprole: in-vivo profile of a bacterical cephalosporin. Clin. Microbiol. Infect. 12(Suppl. 2), 17-22 (2006).
16. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60, 300-311 (2007).
17. Raad I, Darouiche R, Vazquez J et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin. Infect. Dis. 40, 374-380 (2005).
18. Barrett JF. Recent developments in glycopeptides antibacterials. Curr. Opin. Investig. Drugs 6, 781-790 (2005).
19. Stryjewski ME, O'Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40, 1601-1607 (2005).
20. Stryjewski ME, Chu VH, O'Riordan et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50, 862-867 (2006).
21. Laue H, Weiss L, Bernardi A et al. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J. Antimicrob. Chemother. 60, 1391-1394 (2007).
22. Slee AM, Wuonola MA, McRipley RJ et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. 31, 1791-1797 (1987).
23. Brickner SJ, Hutchinson DK, Barbachyn MR et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinones antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. 39, 673-679 (1996).
24. Ford CW, Hamel JC, Stapert D et al Oxazolidinones: new antibacterial agents. Trends Microbiol. 5, 196-200 (1997).
25. La Teana A, Gualerzi CO, Dahlberg AE. Initiation factor IF 2 binds to the α-sarcin loop and helix 89 of Escherichia coli 23S ribosomal RNA. RNA 7, 1173-1179 (2001).
26. Zhou CC, Swaney SM, Shinabarger DL et al. 1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes. Antimicrob. Agents Chemother. 46, 625-629 (2002).
27. Shinebarger DL, Marotti KR, Murray RW et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother. 41, 2132-2136 (1997).
28. Swaney SM, Aoki H, Ganoza MC et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42, 3251-3255 (1998).
29. Kloss P, Xiong L, Shinabarger DL et al. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J. Mol. Biol. 294, 93-101 (1999).
30. Jones RN, Billow CH, Biedenbach DJ et al. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagnost. Microbiol. Infect. Dis. 40, 59-66 (2001).
31. Dickema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 358, 1975-1982 (2001).
32. Bozdogan B, Esel C, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52, 864-868 (2003).
33. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents 23, 113-119 (2004).
34. Wallace RJ Jr, Brown-Elliot BA, Ward SC et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob. Agents Chemother. 45, 764-767 (2001).
35. Brown-Elliot BA, Ward SC, Crist CJ et al. In vitro activities of linezolid against multiple Nocardia species. Antimicrob. Agents Chemother. 45, 1295-1297 (2001).
36. Dong Y, Zhao X, Kreiswirth BN et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44, 2581-2584 (2000).
37. Rodriguez JC, Cebrian L, Lopez M et al. Mutant prevention concentration: a new tool for choosing treatment in non-tuberculous mycobacterial infections. Int. J. Antimicrob. Agents 24, 352-356 (2004).
38. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J. Antimicrob. Chemother. 51(Suppl. S2), ii9-ii16 (2003).
39. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacotherapy 37, 769-774 (2003).
40. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin. Therapeutics 23, 356-391 (2001).
41. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob. Agents Chemother. 41, 465-467 (1997).
42. Rybak MJ, Cappelletty DM, Moldovan T et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis and Enterococcus faecium. Antimicrob. Agents Chemother. 42, 721-724 (1998).
43. Sweeney MT, Zurenko GE. In vitro activity of linezolid combined with other antibacterial agents against staphylococci, enterococci, pneumococci, and selected Gram-negative organisms. Antimicrob. Agents Chemother. 47, 1902-1906 (2003).
44. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2), ii17-ii25 (2003).
45. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 138, 135-142 (2003).
46. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr. Infect. Dis. J. 22, S153-S157 (2003).
47. Stalker DJ, Jungbluth GL, Hopkins NK et al. Pharmacokinetics and tolerance of single and multiple dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J. Antimicrob. Chemother. 51, 1239-1246 (2003).
48. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pbarmacokinet. 42, 1129-1140 (2003).
49. Wynalda MA, Hauer MJ, Wienkers LC. Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab. Dispos. 28, 1014-1017 (2000).
50. Kearns GL, Jungbluth GL, Abdel-Rahman SM et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin. Pharmacol. Ther. 74, 413-422 (2003).
51. Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother. 50, 747-750 (2002).
52. Darley ES, MacGowan AP. Antibiotic treatment of Gram-positive bone and joint infections. J. Antimicrob. Chemother. 53, 928-935 (2004).
53. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn. Microbiol. Infect. Dis. 59, 173-179 (2007).
54. Falagas ME, Siempos II, Papagelopoulos PJ et al. Linezolid for the treatment of adults with bone and joint infections. Int. J. Antimicrob. Agents 29, 233-239 (2007).
55. Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. 50, 73-77 (2002).
56. Myrianthefs P, Markantonis SL, Vlachos K et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob. Agents Chemother. 50, 3971-3979 (2006).
57. Villani P, Regazzi MB, Marubbi F et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob. Agents Chemother. 46, 936-937 (2002).
58. Yogev R, Hendershot PE, Hopkins NK et al. Linezolid: correlation of ventricular fluid and plasma concentrations and pharmacokinetics in pediatric patients and young adults. Presented at: 40th Annual Meeting of the Infectious Diseases Society of America. Chicago, IL, USA, 24-27 October 2002.
59. Zyvox® (linezolid), package insert. Kalamazoo, MI, USA (revised July 2006).
60. Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36, 159-168 (2003).
61. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 51(Suppl. S2), ii45-ii53 (2003).
62. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46, 2723-2726 (2002).
63. Abena PA, Mathieux VG, Scheiff JM et al. Linezolid and reversible myelosuppression. JAMA 286, 1973 (2001).
64. Attassi K, Hershberjer E, Alam R et al. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34, 695-698 (2002).
65. Halpern M. Linezolid-induced pancytopenia. Clin. Infect. Dis. 35, 347-348 (2002).
66. Arellano FM. Linezolid and reversible myelosuppression. JAMA 286, 1973-1974 (2001).
67. Bernstein WB, Trotta RF, Rector JT et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. 37, 517-520 (2003).
68. Palenzuela L, Hahn NM, Nelson RP Jr et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin. Infect. Dis. 40, e113-e116 (2005).
69. DeVriese AS, Coster RV, Smet J et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 42, 1111-1117 (2006).
70. Rucker JC, Hamilton SR, Bardenstein D et al. Linezolid-associated toxic optic neuropathy. Neurology 66, 595-598 (2006).
71. Javaheri M, Khurana R N, O'Hearn TM et al. Linezolid-induces optic neuropathy. Br. J. Ophthalmol. 91, 111-115 (2007).
72. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmarotherapy 27, 1189-1197 (2007).
73. Bressler AM, Zimmer SM, Gilmore JL et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4, 528-531 (2004).
74. Legout L, Senneville E, Gomel JJ et al. Linezolid-induced neuropathy. Clin. Infect. Dis. 38, 767-768 (2004).
75. Rho JP, Sia IG, Crum BA et al. Linezolid-associated peripheral neuropathy. Mayo Clin. Proc. 79, 927-930 (2004).
76. Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 64, 926-927 (2005).
77. Frippiat F, Bergiers C, Michel C et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J. Antimicrob. Chemother. 53, 1114-1115 (2004).
78. McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J. Neuroophthalmol. 25, 18-21 (2005).
79. Saijo T, Hayashi K, Yamada H et al. Linezolid-induced optic neuropathy. Am. J. Ophthalmol. 139, 1114-1116 (2005).
80. Katyare SS, Balasubramanian S, Parmar DV. Effect of corticosterone treatment on mitochondrial oxidative energy metabolism in developing rat brain. Exp. Neurol. 183, 241-248 (2003).
81. Bishop E, Melvani S, Howden BP et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother. 50, 1599-1602 (2006).
82. Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand. J. Infect. Dis. 37, 153-154 (2005).
83. Apodaca AA, Rakita RM. Linezolid-induced lactic acidosis. N. Engl. J. Med. 348, 86-87 (2003).
84. Pea F, Scudeller L, Lugans M et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin. Infect. Dis. 42, 434-435 (2006).
85. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin. Infect. Dis. 43, 180-187 (2006).
86. Bergeron L, Boule M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann. Pharmacother. 39, 956-961 (2005).
87. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 26, 269-279 (2006).
88. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. Clin. Infect. Dis. 34, 1651-1652 (2002).
89. Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M et al. Linezolid-associated serotonin syndrome: what can we learn from cases reported so far? J. Antimicrob. Chemother. 56, 1176-1178 (2005).
90. Boyer EW, Shannon M. The serotonin syndrome. N. Engl. J. Med. 352, 1112-1120 (2005).
91. Kaplan SL, Patterson L, Edwards KM et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr. Infect. Dis. J. 20, 488-494 (2001).
92. Fleishaker DL, Anderson DC, Bruss JB et al. Clinical efficacy of linezolid in the treatment of otitis media. Presented at: 38th Infectious Diseases Society of America. New Orleans, LA, USA, 7-10 September 2000.
93. Saiman L, Goldfarb J, Kaplan SL et al. Safety and tolerability of linezolid in children. Pediatr Infect. Dis. J. 22, S153-S157 (2003).
94. Meissner HC, Townsent T, Wenman W et al. Hematologic effects of linezolid in young children. Pediatr. Infect. Dis. J. 22, S186-S192 (2003).
95. Kohno S, Yamaguchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J. Antimicrob. Chemother. 60, 1361-1369 (2007).
96. Wunderink RG, Rello J, Cammarata S et al. Linezolid versus vancomycin, analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124, 1789-1797 (2003).
97. Kollef MH, Rello J, Cammarata SK et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 30, 388-394 (2004).
98. Maclayton D, Hall RG 2nd. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann. Pharmacother. 41, 235-244 (2007).
99. Dress M, Boucher H. New agents for Staphylococcus aureus endocarditis. Curr. Opin. Infect. Dis. 19, 544-550 (2006).
100. Falagas ME, Manta KG, Ntziora F et al. Linezolid fbr the treatment of patients with endocarditis: a systemic review of the published evidence. J. Antimicrob. Chemother. 58, 273-280 (2006).
101. Jones RN, Ross JE, Fritsche TR et al. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAPPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 57, 279-287 (2006).
102. Tsigrelis C, Singh K V, Coutinho T D et al. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J. Clin. Microbiol. 45, 631-635 (2007).
103. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann. Pharmacother. 41, 296-308 (2007).
104. Ntziora F, Falagas ME. Linezolid for the treatment of patients with atypical mycobacterial infection: a systemic review. Int. J. Tuberc. Lung Dis. 11, 606-611 (2007).
105. Jodlowski TZ, Melnychuk I, Conry J. Linezolid for the treatment of Nocardia spp. infections. Ann. Pharmacother. 41, 1694-1699 (2007).
106. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34, 1481-1490 (2002).
107. Kaplan SL, Deville JG, Yogev R et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J. 22, 677-685 (2003).
108. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptides or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomized controlled trials. Lancet Infect. Dis. 8, 53-66 (2008).
109. Marshall SH, Donskey CJ, Hutton-Thomas R et al. Gene dosage and linezolid resistance in Entecoccus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46, 3334-3336 (2002).
110. Stevens DL, Ma Y, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 195, 202-211 (2007).